



DOI:10.2478/rrlm-2018-0013

Fecal microbiota transplantation in recurrent *Clostridium difficile* infection: the first prospective study of 30 patients in Romania

Mihaela Laszlo^{1*}, Oliviu Pascu^{2,3}, Daniel-Corneliu Leucuta³, Vasile Andreica^{2,3}

1. IRGH Octavian Fodor Cluj Napoca, Romania

2. Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania

3. University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania

Abstract

Introduction: The infection with *Clostridium difficile* has increased in incidence worldwide and it raises many problems with regard to therapy, resistance to treatment and especially recurrence. Recurrence is frequent in patients treated for *Clostridium difficile* infection, requiring vancomycin by mouth, with limited alternatives. The literature shows that one of the most efficient treatment methods in *Clostridium difficile* infection is the transplantation of gut microbiota, also known as fecal microbiota transplantation.

Aim: We present our results following FMT performed in patients with recurrent *Clostridium difficile* infection, and propose a simple and effective protocol for fecal microbiota transplantation.

Study design: The study was prospective. The phases of the FMT procedure: assessment of patient eligibility, patient's consent, identification and screening of donors, discontinuation of antibiotics (vancomycin, metronidazole) 3 days prior to the procedure.

Methods: Between 2013 and 2015, FMT was performed in 30 patients with recurrent *Clostridium difficile* infection, by direct infusion of extensively processed donor fecal matter via colonoscopy. We followed up the patients for 12 months.

Results: Immediate post-transplantation outcome in what concerns stool frequency during the follow-up period (7 days) was encouraging in 93.33% of patients. The donors were healthy individuals (53% 1st degree relatives), previously screened for possible infections and infestations. This result was sustained at 6-month and 12-month follow-up. Post-transplantation recurrence occurred in 6.67% (2 patients), which responded well to treatment and did not require a new vancomycin course.

Conclusions: Fecal microbiota transplantation via colonoscopy is effective, safe, easy to perform, it yields lasting results and is therefore a good option for recurrent or treatment-resistant *Clostridium difficile* infection.

Keywords: *Clostridium difficile*, recurrence, fecal transplantation, donor

Received: 1st December 2017; Accepted: 14th March 2018; Published: 19th March 2018

*Corresponding author: Laszlo Mihaela, IRGH Octavian Fodor Cluj Napoca, Romania
E-mail: miham83@yahoo.com

Introduction

Clostridium difficile is a mobile, anaerobic gram-positive bacillus which is commonly present in the colon bacterial flora in more than 50% of children under the age of one, and this percentage reduces to about 3% in adults. About a quarter of the persons who had infections caused by *Clostridium difficile* species relapse, either because the initial infection was not completely healed, or because they come in contact with a new strain [1,2,3]. This actual epidemic is acknowledged by many countries, with reports from Europe [4], Taiwan [5] and Korea [6]. In Romania, the increase in *Clostridium difficile* infection (CDI) incidence and severity has been reported since the first months of 2011 - with the onset of the etiological investigation of CDI-compatible pathology [3].

For mild cases of CDI, supportive therapy, along with discontinuation of the antibiotic treatment that produced the infection and therapy with Metronidazole for 10-14 days, may be sufficient; moderate and persistent cases, however, require 10 to 14 days of oral metronidazole/vancomycin or both.

Fidaxomicin is a new macrocyclic antibiotic, which selectively eradicates *Clostridium difficile* and was shown to have rates of clinical recovery comparable to vancomycin; however, it, too, is very expensive.

Despite these therapeutic options, the disease relapses in up to 5-35% of cases after initial therapy with metronidazole and vancomycin, and recurrences are more difficult to manage [7].

Possible alternatives and auxiliary options include fecal microbiota transplantation, intravenous immunoglobulin and monoclonal antibody therapy [8], but none have been studied in terms of efficacy and long-term side effects.

The fecal microbiota transplantation (FMT), also known as “fecal transplantation”, is rapidly gaining in acceptance as a viable, safe and effective

tive treatment for recurrent *Clostridium difficile* infection.

FMT in CDI theoretically works by replacing or consolidating the protective colonic microbiota, which was disrupted by antibiotics and/or iatrogenic factors [9]. Once disturbed, the normal intestinal flora loses its ability to self-protect becoming vulnerable, allowing germs such as *Clostridium difficile* to dominate. FMT recreates a balanced colonic microbiota, resisting colonisation and suppressing *Clostridium difficile* [10].

The first report on the use of FMT for the treatment of CDI was published in 1983; a patient experienced prompt and complete remission of gastro-intestinal symptoms after receiving a FMT [11].

Although the impact of FMT on the immune system is complex and unpredictable, important research on the effect of these microbes on the host is under way.

FMT for recurrent CDI is not yet the “standard/ acknowledged” therapy; nevertheless, its rate of success constantly exceeds 90% [12]; it is the adequate option for patients unable to clear the infection despite traditional management.

In this article, we aim to summarize the information on this therapeutic option, focusing on its methodology, in order to facilitate its application and acceptability.

Material and methods

Patients

FMT was performed in 30 patients between December 2014 - January 2016. Informed consent was obtained from all individual participants included in the study. All patients had experienced at least one recurrence of *Clostridium difficile* infection after standard treatment with metronidazole and vancomycin (10-14 days). We mention that out of the 30 patients enrolled in the study, one patient was minor. There were

no patients who were intolerant to both therapies according to the protocol.

All patients signed an informed consent, which included a discussion on the standard colonoscopy, the risks of sedation, haemorrhage and perforation, as well as the infection and allergy risks. All possible reactions to FMT were discussed and documented.

The patients were instructed to discontinue the antibiotics 2 to 3 days before the procedure. The preparation for colonoscopy involved a 4000 macrogol solution (Fortrans) on the day preceding the FMT.

At 1 month, 6 and 12 months post FMT, patients were presented in outpatient clinic to for harvesting of toxin A and B.

The participants were excluded from the analysis if their CD antibiotic therapy had been incomplete (less than 80% of the standard cure), the first episode of infection, or in case the A and B toxins were negative after antibiotic therapy and the patient was symptomatic. There were a total of 70 cases of *Clostridium difficile* in the period December 2014 - January 2016.

Study design

The study was approved by the Ethics Committee of "Octavian Fodor" Regional Institute of Gastroenterology and Hepatology, Cluj Napoca 17649/ 3 December 2014 and Ethics Committee of the University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca – 269/ 6 December 2014.

The phases of FMT procedure were: assessment of patient eligibility, patient's consent, identification and screening of donors, discontinuation of antibiotics (vancomycin, metronidazole) 3 days prior to the procedure.

Total hospitalization for FMT for each patient was approximately 17 days:

-the 7-day pre-screening period, reserved for: signing the informed consent, filling in the questionnaire of bowel movement assessment,

according to the Bristol scale (number of bowel movements/day, consistency), applying the inclusion and exclusion criteria, lab tests (erythrocyte sedimentation rate -ESR, C reactive protein- CRP), identifying and collecting samples from donors.

- the fecal transplant, 3-5 days: pre-administration period (1-2 days) for collecting stool samples; administration of the fecal transplant (1 day) and the post administration period (1-2 days) for collecting stool samples, inflammatory tests (ESR, CRP) and monitoring clinical symptoms (fever, pain).
- follow-up period in hospital after FMT (3-5 days): questionnaire of bowel movement assessment, according to the Bristol scale (number of bowel movements/day, consistency), stool samples.

We used a questionnaire for the assessment of stool consistency and frequency, according to the Bristol scale, in the pre-screening and follow-up periods [15].

Another questionnaire was used for assessment of compliance with the antibiotic treatment for *Clostridium difficile* infection; it included information on the number of antibiotic courses administered until FMT, on whether other antibiotics were prescribed for another infection before identification of *Clostridium difficile*, and on adverse effects, both general (fever) and digestive (nausea, bloating, abdominal pain).

All patients were followed up for 12 months after FMT by telephone (every week of the first month after FMT, then every month for 11 months), and were re-admitted in case of complications.

Donors

The potential stool donors were identified by the subjects themselves, being relatives of grade I or II and in some patients being the wife/ husband.

The donors were excluded if they had taken antibiotics 90 days prior to procedure or in case they did not meet the eligibility criteria: stool screening- ova and parasite exam, stool culture (usually includes: *Salmonella*, *Shigella*, *Escherichia coli*, *O157:H7*, *Yersinia enterocolitica*, and *Campylobacter*), *Clostridium difficile* toxins A and B, rotavirus antigen; serology- HIV-1 and HIV-2, Hepatitis A, B and C; gastrointestinal comorbidities - history of inflammatory bowel disease, history of irritable bowel syndrome, chronic constipation or diarrhoea, history of gastrointestinal malignancies; other conditions - atopy, autoimmune conditions, such as multiple sclerosis, fibromyalgia, chronic fatigue syndrome.

FMT procedure

The fecal suspension (~ 150 ml) was diluted in 0.9 % sterile saline solution up to a volume of 400-425 ml. Subsequently, the suspension was filtered several times. This suspension was poured into a sterile vial and administered within one hour. The administration method was trans-colonic via colonoscopy to the ileum in 90% of patients and 10% to the level of the cecum, after standard preparation (Fortrans split - in doses that varied according to each patient's bowel transit).

The patients received 4 mg of loperamide in order to reduce gut motility immediately after FMT and 6 hours after the procedure. Patients received a normal diet after about 5 hours. Serological tests were evaluated every day. The patients were discharged at 3 days after FMT.

Three days prior and after the procedure the patients no longer received vancomycin or metronidazole. For the following 7 days, the patients were asked to report any possible symptoms (fever, bloating, abdominal pain).

Statistic analysis

Categorical data was described as counts and percentages. Continuous normally distributed

data were presented as means and standard deviations (SD), while data non following the normal distribution were presented as medians and interquartile ranges (IQR) and ranges. Confidence intervals of 95% were used for means and bootstrapped ones for medians. Normality of the data was assessed with quantile-quantile plots, strip-charts and Shapiro-Wilk tests. We used the Friedman test to compare repeated measurements of non-normally distributed data, the Kruskal-Wallis test (to compare multiple independent groups regarding non-normally distributed continuous variables) and the Fisher exact test (to assess the dependence between categorical variables). We considered two tailed p-values <0.05 to be statistically significant. R environment for statistical computing and graphics, version 3.2.3 was used for all statistical computations.

Results

We enrolled 30 patients (14 females, 16 males), aged between 5 and 83 years; all patients had had at least one relapse of *Clostridium difficile* infection, with a mean of 2 (table I, II). The duration of CDI infection until the FMT ranged between 4 and 8 months. Twenty-one patients underwent vancomycin and metronidazole therapy according to protocol (vancomycin 500 mg every 6 hours and metronidazole 500 mg every 8 hours by mouth for 14 days), repeated for each relapse, while the remaining 9 patients received either metronidazole (4 patients) or vancomycin (5 patients), dosed according to protocol. The 9 patients required a different therapy due to intolerance to one of the antibiotics. The treatment described has been done for previous recurrences and not for the current episode. The number of bowel movements ranged between 3 and 15/day, with a mean of 7.6.

A single patient had no associated conditions (a hospital worker); the others had various comorbidities associated with decreased immune

Table I. Clinical and laboratory characteristics of patients

Characteristic	Mean (SD)/Median (IQR)	range
Age, mean (SD)	57.8 (16.27)	5 - 83
Nr bowel movements at 7 days before FMT, median (IQR)	7 (6-10)	3 - 15
Nr relapses, mean (SD)	2 (0.91)	1 - 4
CRP (mg/l), median (IQR)	3.58 (1.21 - 16.5)	0.4 - 28
ERS (mm/h), median (IQR)	35 (20 - 56.75)	6 - 105
Hb (g/l), mean (SD)	11.71 (1.32)	8 - 14.6
Nr bowel movements at 7 days after FMT, mean (SD)	2 (1-3)	1 - 4
Toxin A and B after FMT, median (IQR)	0.03 (0.02 - 0.27)	0 - 0.9
CRP (mg/l) after FMT, median (IQR)	1 (0.7 - 7.5)	0.4 - 20
ESR (mm/h) after FMT, median (IQR)	21 (20 - 40)	6 - 80
Nr bowel movements at 6 months, median (IQR)	1 (1 - 2)	1 - 3
Nr bowel movements at 1 year, median (IQR)	1.5 (1 - 2)	1 - 3

(SD – standard deviation, IQR – interquartile range, FMT-fecal microbiota transplantation, ESR – erythrocyte sedimentation rate, CRP – C reactive protein, Hb – haemoglobin)

response or with requirement for antibiotic therapy (table II). The most used antibiotics were ceftriaxone, ciprofloxacin and amoxicillin-clavulanate. The mean number of relapses of CDI was 2.33 in patients treated with vancomycin and metronidazole, 1.5 in patients treated with vancomycin and 1 in those treated with metronidazole - a statistically significant difference between them (the metronidazol group being statistically significant, different than vancomycin and metronidazole group regarding the number of relapses, in the post-hoc pairwise comparisons $p=0.004$) (tabel III).

All patients tolerated colonoscopy well. In 17 patients, the aspect of the colonic mucosa was normal; in 7 patients we found ulceration on certain segments of the colon, while in other 6 patients we found pseudomembranes.

After FMT, some patients developed certain clinical symptoms, as follows: fever (8 patients) in the first 3 days post FMT, which remitted spontaneously after the 3 days. Two patients experienced severe abdominal pain in the first 2

days post FMT, which responded to pain medication (tabel IV). The rest experienced moderate (10 patients) and mild pain (13 patients) that did not require medication.

Even though it is not an important breakthrough in view of the number of patients and the fact that it did not influence the results of the study, there was a slight increase in inflammatory markers relative to baseline levels.

Approximately 7 days after FMT 2 patients experienced a CDI relapse, with clinical symptoms and toxin A and B positive *Clostridium* strains; the remaining 28 patients did not experience any post FMT relapses, had no toxin positive strains and no symptoms in the following 12 months. The 2 relapsing patients had to undergo another vancomycin and metronidazole protocol for 14 days after FMT, followed by a relapse-free period during the rest of the 12 months of follow-up.

The post-FMT outcome in 28 patients was favourable (had no toxin positive strains and no symptoms), with a statistically significant im-

Table II. Clinical characteristics pre transplantation

Characteristic	Number (%) (n=30)
Female	14/30 (46.67)
Number relapses	1: 10/30 (33.33) 2: 12/30 (40) 3: 6/30 (20) 4: 2/30 (6.67)
Antibiotics for <i>Clostridium difficile</i>	Metronidazole: 5/30 (16.67) Vancomycin: 4/30 (13.33) Vancomycin and Metronidazole: 21/30 (70)
Colonoscopy	normal: 17/30 (56.67) pseudomembranes: 6/30 (20) ulcerations: 7/30 (23.33)
Associated conditions	Gastric adenocarcinoma, under chemotherapy: 1/30 (3.33) Lung diseases: 8/30 (26.67) Urinary diseases: 3/30 (10) Caroli disease: 1/30 (3.33) Liver cirrhosis: 10/30 (33.33) IgA deficiency: 1/30 (3.33) No associated conditions: 1/30 (3.33) Acute pancreatitis: 1/30 (3.33) Heart diseases: 4/30 (13.33)
Donor	1 st degree relative: 16/30 (53.33) 2 nd degree relative: 4/30 (13.33) wife: 8/30 (26.67) husband: 2/30 (6.67)
Relapse	2/30 (6.67)
Antibiotics administered pre transplantation for other conditions	Amoxicillin: 5/29 (17.24) Amoxicillin-clavulanate: 4/29 (13.79) Trimetoprim-Sulfamethoxazole: 2/29 (6.9) Ceftriaxone: 9/29 (31.03) Ciprofloxacin: 5/29 (17.24) Colistin: 2/29 (6.9) Meropenem: 1/29 (3.45) Imipenem-cilastatin: 1/29 (3.45)

Table III. Mean number (standard deviation) of relapses, according to antibiotherapy for *Clostridium difficile*.

Antibiotherapy	metronidazol (n=5)	vancomycin (n=4)	vancomycin and metronidazol (n=21)	P-value
Number relapses, mean (SD)	1 (0)	1.5 (0.58)	2.33 (0.86)	0.003

SD – standard deviation; CI – confidence interval; differences between groups: vancomycin vs. metronidazol = 0.5 (95% CI -0.76 – 1.76, p=0.590); vancomycin and metronidazole vs. metronidazole = 1.33 (95% CI 0.39 - 2.27, p=0.004); vancomycin and metronidazole vs. vancomycin = 0.83 (95% CI -0.19 – 1.86, p=0.127)

Table IV. Clinical characteristics post transplantation

Nr bowel movements at 7 days after transplantation	1: 9/30 (30) 2: 12/30 (40) 3: 8/30 (26.67) 4: 1/30 (3.33)
Fever after transplantation	8/30 (26.67)
Abdominal pain after transplantation	no: 4/30 (13.33) yes: 1/30 (3.33) mild: 13/30 (43.33) moderate: 10/30 (33.33) severe: 2/30 (6.67)
Nr bowel movements at 6 months	1: 17/28 (60.71) 2: 6/28 (21.43) 3: 5/28 (17.86)
Nr bowel movements at 1 year	1: 14/28 (50) 2: 12/28 (42.86) 3: 2/28 (7.14)

provement in the mean number of bowel movements at 7 days/ 6 months/ 1 year ($p < 0.001$) (tabel V).

The choice of donors was found to be important in all recipients due to personal safety, even if there is no statistical significance ($p = 0.43$) for the relationship between relapse and donor (the “1st and 2nd degree relative” group) in our population. Sixteen patients chose a 1st degree relative donor, 8 patients chose their wife, 4 patients a 2nd degree relative and 2 patients, their husband.

We found a statistically significant relation between type of donor and number of bowel movements only at 6 months post FMT ($p = 0.01$), but not at 1 year ($p = 0.82$) (table VI).

Table V Number of bowel movements at different times (before transplantation, 7 day after transplantation, at 6 months and at 1 year)

Time:	before	7 days	Difference (95% CI)	P-value
Number of bowel movements, median (IQR)	7 (6 - 10)	2 (1 - 3)	-5 (-6.5 - -4.5)	< 0.001
Time:	before	6 months		
Number of bowel movements, median (IQR)	7 (5.75 - 10)	1 (1 - 2)	-6 (-7 - -5)	< 0.001
Time:	before	1 year		
Number of bowel movements, median (IQR)	7 (5.75 - 10)	1.5 (1 - 2)	-5.5 (-7 - -4.5)	< 0.001
Time:	7 days	6 months		
Number of bowel movements, median (IQR)	2 (1 - 3)	1 (1 - 2)	-1 (-1.5 - -0.5)	0.017
Time:	6 months	1 year		
Number of bowel movements, median (IQR)	1 (1 - 2)	1.5 (1 - 2)	0.5 (-1 - 1)	1

IQR – interquartile range; CI – confidence interval

Table VI. Median number (1st quartile – 3rd quartile) of bowel movements/day after transplantation (at 7 days, 6 months and 1 year), according to type of donor

Donor:	1 st degree relative (n=16)	2 nd degree relative (n=4)	Wife (n=8)	Husband (n=2)	P-value
Number of bowel movements/day, at 7 days	2 (1.75 - 3)	1 (1 - 1.25)	2 (1.75 - 2.25)	3 (3 - 3)	0.075
Number of bowel movements/day at 6 months	1 (1 - 1)	3 (2 - 3)	1.5 (1-2)	2.5 (2.25-2.75)	0.04
Number of bowel movements/day at 1 year	1 (1 - 2)	1 (1 - 1.5)	2 (1-2)	2 (1.5 - 2.5)	0.828

Discussion

This 30-case series, the first prospective study published in Romania, of relapsing CDI patients treated with FMT using colonoscopy, provides effectiveness of the procedure for this condition.

Even though the literature generally recommends FMT from the third recurrence [13], in this study we are trying to track the evolution of patients after FMT since the first relapse.

Although there is a limited number of patients in this study, the high success rate of FMT in recurrent CDI has been observed (2 relapses out of the total of 30), as literature suggests [13,14]. The post-FMT outcome in 28 patients was favourable (had no toxin positive strains and no symptoms in the following 12 months).

As for the laboratory tests, all patients had a mild increase in inflammatory markers with respect to their initial levels (ESR and CRP) in the first week after FMT, but with subsequent return within normal range, as described in the literature [14]. Even though it did not show any impact on our study and there was a small number of patients, we mentioned this change in laboratory samples as it is also described in the literature.

Approximately 20% of patients infected with *Clostridium difficile* treated with antibiotics will experience a relapse within the first 6 months from discontinuation of the treatment [15]. The treatment options for relapsing *Clostridium difficile* are limited. ACG (The American College of Gastroenterology) recommends FMT after the 3rd relapse [16,17,18] in order to re-establish the normal composition of the intestinal flora, restore the metabolic balance and stimulate both cellular and humoral immune responses in the intestinal mucosa. The fecal matter transplantation has been used ever since the 4th century in China, and it is increasingly accepted nowadays as a safe and effective method for the treatment of relapsing *Clostridium difficile* infections.

Clinical research is increasingly supplying information on the role of the intestinal microbiota in chronic diseases, such as IBD (Crohn's disease and ulcerative colitis), metabolic syndrome, various cancers and obesity [19].

In order to avoid adverse events, a vital stage in the preparation of FMT is the donor screening, which should include detailed laboratory tests. It is of utmost importance to ensure that the donors are healthy, without evidence of autoimmune diseases or other chronic conditions. Certain adverse events related to the FMT treatment have, however, been reported. Brandt and colleagues reported that in the long term, the 77 patients they were following up did not experience any infection post colonoscopy FMT, but that 4 patients later presented with new diseases – peripheral neuropathy, Sjogren's syndrome, idiopathic thrombocytopenic purpura and rheumatoid arthritis [20]. Others experienced improvement of pre-existent conditions, such as allergies, sinusitis and arthritis. These new diseases, as well as improvements of old diseases, cannot be directly linked to the FMT, but incite to further research on the interaction of the microbiota and autoimmune diseases [11,19-21].

The infusion of stool via colonoscopy has several advantages over other methods (enema, nasogastric tube, gastroscopy). Firstly, this method ensures infusion of stool on the entire length of the colon. Secondly, the colonic mucosa can be visualised directly and any abnormal aspects can be documented. Thirdly, the patients are sedated and generally tolerate the FMT well. In addition, the success rates range from 86% to 100%, while the success rate for enema range from 81% to 100% [22]. Nevertheless, FMT via colonoscopy may incur risks of perforation, infection, bleeding and pain. Although the nasogastric method is less efficient, with rates of success between 73% and 83%, it is easier to perform, less expensive, and has lower risks for the patient [23, 24]. In our case, colonoscopy was

considered more effective even if it presents certain risks. It was possible to visualize the entire colon mucosa and we could spread the prepared solution to the right side of the colon for better effectiveness. The “preferred donor” is usually someone sharing an intimate environment with the patient [23, 25].

Considering that each method of infusion has its advantages and disadvantages, the best method should be individualised for each patient.

We are aware of the limitations of our study: the limited number of subjects, the lack of a control group. Despite the strong belief of some practicing physicians in the effectiveness and safety of FMT, a randomised controlled trial may be necessary before this treatment is approved in the medical community. The standard donor, the optimal screening and treatment protocols should also be developed and validated

Conclusion

FMT for recurrent *Clostridium difficile* infections can be an effective and durable method of treatment for patients resistant to traditional treatment.

Transplantation of faecal suspension obtained from healthy donors may restore normal microbiota, breaking the cycle of recurrent CDI, usually after traditional treatment.

In most cases (28 patients), symptoms improved at 7 days of FMT procedure and patients stayed diarrhoea free for 12 months (our follow-up), indicating that FMT could be an effective alternative in the treatment of patients with recurrent/refractory CDI.

The only question that remains related to FMT is what will be the side effects over time?

As the *Clostridium difficile* “epidemics” show, an increasing number of patients with recurrent or refractory infections will be able to benefit from this method of treatment.

Despite not having any element of novelty, our study aims to provide yet another argument

in favour of fecal microbiota transplantation and its importance and necessity in the treatment of recurrent *Clostridium difficile* infection.

Our study, the first prospective study of its kind in Romania, demonstrates the availability, simplicity and immediate and long-term effectiveness of FMT.

Conflict-of-interest statement

We declare that we have no conflicts of interest.

Abbreviations

CDI- *Clostridium difficile* infection

CD - *Clostridium difficile*

FMT- fecal microbiota transplantation

SD - standard deviations

IQR- interquartile ranges

ACG - The American College of Gastroenterology

References

1. Bartlett JG. Clinical practice. Antibiotic associated diarrhea. N Engl J Med. 2002 Jan;346(5):334-9. DOI: 10.1056/NEJMcp011603
2. McFarland LV. Renewed interest in a difficult disease: *Clostridium difficile* infections – epidemiology and current treatment strategies. Curr Opin Gastroenterol. 2009 Jan;25(1):24-35. DOI: 10.1097/MOG.0b013e-32831da7c4
3. Epuran S, Rusu E, Sbarcea A, Musat S. *Clostridium difficile* – etiology and epidemiology. Revista romana de boli infectioase 2014;1:28-30
4. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, et al. *Clostridium difficile* infection in Europe: a hospital based survey. Lancet. 2011 Jan;377(9759):63-73. DOI: 10.1016/S0140-6736(10)61266-4
5. Lee YC, Wang JT, Chen AC, Sheng WH, Chang SC, Chen YC. Changing incidence and clinical manifestations of *Clostridium difficile*-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. J Microbiol Immunol Infect. 2012 Aug;45(4):287-95. DOI: 10.1016/j.

- jmii.2011.12.001
6. Ray A, Smith R, Breaux J. Fecal microbiota transplantation for *Clostridium Difficile* infection: The Ochsner Experience. *Ochsner J.* 2014 Winter; 14(4): 538–44.
 7. Bakken JS. Fecal bacteriotherapy for recurrent *Clostridium difficile* infection. *Anaerobe* 2009; 15:285. DOI: 10.1016/j.anaerobe.2009.09.007
 8. Rubin TA, Gessert CE, Aas J, Bakken JS. Fecal microbiome transplantation for recurrent *Clostridium difficile* infection: report on a case series. *Anaerobe*. 2013 Feb;19:22-6. DOI: 10.1016/j.anaerobe.2012.11.004
 9. Grehan MJ, Borody TJ, Leis SM, Campbell J, Mitchell H, Wettstein A. Durable alteration of the colonic microbiota by the administration of donor fecal flora. *J Clin Gastroenterol.* 2010 Sep;44(8):551-61. DOI: 10.1097/MCG.0b013e3181e5d06b
 10. Brandt LJ, Reddy SS. Fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *J Clin Gastroenterol.* 2011 Nov;45 Suppl:S159-67. DOI: 10.1097/MCG.0b013e318222e603
 11. Bang BW, Park JS, Kim HK, Shin YW, Kwon KS, Kwon HY, et al. Fecal Microbiota Transplantation for Refractory and Recurrent *Clostridium difficile* Infection: A Case Series of Nine Patients. *Korean J Gastroenterol.* 2017 Apr 25;69(4):226-31. DOI: 10.4166/kjg.2017.69.4.226
 12. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. *Clin Infect Dis.* 2011 Nov;53(10):994-1002. DOI: 10.1093/cid/cir632
 13. Michael B. Edmond. The power of poop: Fecal microbiota transplantation for *Clostridium Difficile* infection. *Trans Am Clin Climatol Assoc.* 2016; 127: 71–80.
 14. Konturek PC, Koziel J, Dieterich W, et al. Successful therapy of *Clostridium difficile* infection with fecal microbiota transplantation. *J Physiol Pharmacol.* 2016 Dec;67(6):859-66.
 15. Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, Finney J, et al. Predictors of First Recurrence of *Clostridium difficile* Infection: Implications for Initial Management. *Clin Infect Dis.* 2012 Aug; 55(2): S77–S87. DOI: 10.1093/cid/cis356
 16. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *Am J Gastroenterol.* 2013 Apr;108(4):478-98. DOI: 10.1038/ajg.2013.4
 17. Boyle ML, Ruth-Sahd LA, Zhou Z. Fecal Microbiota Transplant to Treat Recurrent *Clostridium difficile* Infections. *Crit Care Nurse.* 2015 Apr;35(2):51-64. DOI: 10.4037/ccn2015356
 18. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of *Clostridium difficile*-associated disease. *Aliment Pharmacol Ther.* 2012 Apr;35(8):865-75. DOI: 10.1111/j.1365-2036.2012.05033.x
 19. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Health Epidemiology of America (SHEA) and the Infectious Diseases Society of America. *Infect Control Hosp Epidemiol.* 2010 May;31(5):431-55. DOI: 10.1086/651706
 20. Festi D, Schiumerini R, Birtolo C, Marzi L, Montrone L, Scaiola E, et al. Gut microbiota and its pathophysiology in disease paradigms. *Dig Dis.* 2011;29(6):518-24. DOI: 10.1159/000332975
 21. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent *Clostridium difficile* infection. *Am J Gastroenterol.* 2012 Jul;107(7):1079-87. DOI: 10.1038/ajg.2012.60
 22. Mattila E, Uusitalo-Seppala R, Wuorela M, Lehtola L, Nurmi H, Ristikankare M et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent *Clostridium difficile* infection. *Gastroenterology.* 2012 Mar;142(3):490-6. DOI: 10.1053/j.gastro.2011.11.037
 23. Aas J, Gessert CE, Bakken JS. Recurrent *Clostridium difficile* colitis: a series involving 18 patients treated with donor stool administered via a nasogastric tube. *Clin Infect Dis.* 2003 Mar;36(5):580-5. DOI: 10.1086/367657
 24. Rao K, Safdar N. Fecal microbiota for the treatment of *Clostridium Difficile* infection. *J Hosp Med.* 2016 Jan;11(1):56-61. DOI: 10.1002/jhm.2449
 25. Gupta A, Khanna S. Fecal microbiota transplantation. *JAMA.* 2017 July;318(1):102. DOI: 10.1001/jama.2017.6466